FDA Approves Medtronic's MiniMed Paradigm Real-Time Revel System

Medtronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm(R) REAL-Time Revel(TM) System, the next generation of the industry's only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software). The system incorporates new innovative CGM features including predictive alerts that can give early warning to people with diabetes so they can take action to prevent dangerous high or low glucose events.

The MiniMed Paradigm Revel System, our second generation integrated system, incorporates new innovative CGM features including predictive alerts that can warn you of oncoming lows or highs so you can take action sooner to gain greater control. With precise insulin delivery and integrated CGM technology, the Paradigm Revel System gives you the peace of mind you want and the freedom you deserve. (CGM components sold separately.)

Medtronic has received FDA approval for its integrated diabetes management system called MiniMed Paradigm REAL-Time Revel System. The system combines insulin pump therapy, continuous glucose monitoring and diabetes therapy management software. It features predictive alerts which signal trends in blood glucose levels notifying patients to take preventive measures. For maximal comfort it can be combined with the Medtronic wireless continuous glucose monitoring system and measurements can be uploaded to the online Carelink personal management software. The system is made available immediately in five different colors.

This state-of-the-art system gives you the control of an insulin pump plus real-time glucose monitoring. The MiniMed Paradigm Real-Time Revel System helps you take immediate corrective or preventative action to keep your glucose levels healthy and prevent diabetes-related complications.